Cargando…
Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape
Over the last several decades, a number of new treatment options for patients with hepatocellular carcinoma (HCC) have been developed. While treatment decisions for some patients remain clear cut, a large numbers of patients have multiple treatment options, and it can be hard for multidisciplinary t...
Autores principales: | Young, Shamar, Hannallah, Jack, Goldberg, Dan, Sanghvi, Tina, Arshad, Junaid, Scott, Aaron, Woodhead, Gregory |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380625/ https://www.ncbi.nlm.nih.gov/pubmed/37511193 http://dx.doi.org/10.3390/ijms241411434 |
Ejemplares similares
-
Role of the Interventional Radiologist in the Treatment of Desmoid Tumors
por: Goldberg, Daniel, et al.
Publicado: (2023) -
Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review
por: Young, Shamar, et al.
Publicado: (2018) -
Ferroptosis: friend or foe in cancer immunotherapy?
por: Demuynck, Robin, et al.
Publicado: (2023) -
Estrogens in Hepatocellular Carcinoma: Friends or Foes?
por: Carruba, Giuseppe
Publicado: (2021) -
Interleukin-21 in cancer immunotherapy: Friend or foe?
por: Stolfi, Carmine, et al.
Publicado: (2012)